CClinicalTrials.gg
Status unknownNCT02982226Updated Apr 21, 2020

ReNu™ vs. Corticosteroids for the Treatment of Plantar Fasciitis

An interventional study of ReNu Injection and Corticosteroid Injection in Fasciitis, Plantar, sponsored by NuTech Medical, Inc. Status unknown at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-21.

Sponsored by NuTech Medical, Inc · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The objective of this clinical trial is to evaluate both the safety and efficacy of the ReNu™ injection on pain and inflammation in subjects diagnosed with plantar fasciitis as compared to a Corticosteroid Injection which is considered standard of care.

Read the detailed description

This is a two (2) arm evaluation in 150 subjects with plantar fasciitis. Patients will be treated with ReNu™(study treatment) or Corticosteroids (control).

At each follow-up visit, concomitant medications and adverse events shall be collected from each subject, and each subject shall complete following questionnaires:

  • AOFAS Ankle-Hindfoot Score (AOFAS-AHS)
  • Visual Analog Score (VAS)
  • Single Answer Numeric Evaluation (SANE)
  • Subject Satisfaction Score (at the 6 Month Follow Ups ONLY)

The subjects will be assessed at Baseline (pre-injection) using these scales and again at all subsequent study follow-up visits.

02

Conditions studied

  • Fasciitis, Plantar

Keywords

  • Plantar Fasciitis
  • Jogger's Heel
  • ReNu
03

In context

Fasciitis

235 studies on the registry are indexed under Fasciitis; 37 are open to participants now.

This study's planned enrollment of 150 is above the median of 54 across 192 interventional studies indexed under Fasciitis.

Browse Fasciitis studies →

Lead sponsor

NuTech Medical, Inc is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Ages 18 to 75 inclusive
  2. BMI less than 40
  3. Actively practicing a contraception method, abstinent, surgically sterile, or post-menopausal (defined as no menses for a minimum of 12 months)
  4. Reporting heel pain of >6 on a verbally administered 1-10 pain scale where 1 is no pain and 10 is extreme pain
  5. Diagnosed with plantar fasciitis in either foot
  6. Completed a minimum of two months of conservative, non-injection treatment/therapies (i.e., activity modification, icing, NSAIDs, orthotics, physical therapy, etc.)

Exclusion criteria

Exclusion Criteria

  1. Prior surgery on the affected foot
  2. Prior injection treatment for plantar fasciitis within the past 6 months with steroids or tissue engineered materials just in the site seeking treatment
  3. Clinical signs and symptoms of infection of foot in question
  4. Evidence of significant neurological disease of either foot
  5. Non-ambulatory
  6. Presence of comorbidities that can be confused with or can exacerbate the condition including, but not limited to the following:

    • Calcaneal stress fracture
    • Nerve entrapment syndrome, such as Baxter's Nerve Entrapment or Tarsal Tunnel Syndrome
    • Plantar Fascial rupture
    • Systemic disorders associated with enthesiopathy, i.e., Gout, Reiter's syndrome, rheumatoid arthritis, etc.
    • Achilles tendonitis
    • Fat Pad Atrophy
    • Fibromyalgia
    • Diabetic Neuropathy
  7. Pregnant, pregnant within the past six (6) months, breast feeding and/or desire to become pregnant during the course of the study, as verified by urine pregnancy test within one week prior to injection.
  8. Has taken NSAID medication within the past 14 days, or other pain medication in the past day
  9. History of more than two (2) weeks treatment with immuno-suppressants, including systemic corticosteroids or cytotoxic chemotherapy within one month prior to initial screening, or has receive such medications during the screening period, or are anticipated to require such medications during the course of the study.
  10. Taking any investigational drug(s) or therapeutic device(s) within 30 days preceding screening
  11. History of radiation therapy of the affected foot
  12. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV
  13. Involved in a Worker's Compensation Claim of any kind
  14. Unable to understand the objectives of the trial
  15. Presence of any condition(s) which, in the opinion of the investigator, would compromise the subject's ability to complete this study
  16. Having a known history of poor adherence with medical treatment.
  17. Express an unwillingness to receive human allograft tissue
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    ReNu Injection

    Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.

    Other: ReNu Injection

  • Active comparator
    Corticosteroid Injection

    Plantar Fascia injection with Corticosteroids.

    Other: Corticosteroid Injection

Interventions

  • OtherReNu Injection

    ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.

  • OtherCorticosteroid Injection

    Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis

06

What researchers measure

Primary outcomes

  1. Change in AOFAS score from baseline

    Time frame: 6 months

Secondary outcomes

  1. Change in VAS pain score from baseline

    Time frame: 6 months

  2. Change in SANE function score from baseline

    Time frame: 6 months

  3. Return to Normal Function between treatment groups

    Assessed using questionnaire by the Principal Investigator (PI)

    Time frame: 6 months

07

Study locations

6 sites
  • Advanced Orthopedics
    Denver, Colorado 80230, United States
  • Orlando Food and Ankle Clinic
    Orlando, Florida 32806, United States
  • The Iowa Clinic Foot and Ankle Surgery
    West Des Moines, Iowa 50266, United States
  • Lower Extremity Institute of Research & Therapy (LEIRT)
    Poland, Ohio 44514, United States
  • Geisinger
    Danville, Pennsylvania, United States
  • The Vancouvover Clinic
    Vancouver, Washington 98686, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02982226
Lead sponsor
NuTech Medical, Inc
Collaborators
MileStone Research Organization, Organogenesis
Responsible party
Sponsor
First posted
Dec 5, 2016
Start date
Sep 2016
Primary completion
Apr 2021 (estimated)
Completion
Apr 2021 (estimated)
Last update
Apr 21, 2020

Study contacts

Alan Ng, DPM, FACFAS
principal investigator · Advanced Orthopedics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion